Denosumab Decreases Epicardial Adipose Tissue Attenuation in Dialysis Patients with Secondary Hyperparathyroidism and Low Bone Mass.

IF 2.4 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiorenal Medicine Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI:10.1159/000535882

Chien-Liang Chen, En-Shao Liou, Ming-Ting Wu

{"title":"Denosumab Decreases Epicardial Adipose Tissue Attenuation in Dialysis Patients with Secondary Hyperparathyroidism and Low Bone Mass.","authors":"Chien-Liang Chen, En-Shao Liou, Ming-Ting Wu","doi":"10.1159/000535882","DOIUrl":null,"url":null,"abstract":"Introduction: Denosumab preceding elective surgery is an alternative option when parathyroidectomy is not immediately possible. Denosumab (an osteoprotegerin mimic) may play a role in the cardiovascular system, which is reflected in the features of epicardial adipose tissue (EAT) and coronary artery calcification (CAC).Methods: We investigated the effects of denosumab on EAT attenuation (EATat) and CAC in dialysis patients with secondary hyperparathyroidism (SHPT). This cohort study included patients on dialysis with SHPT. The baseline characteristics of dialysis patients and propensity score-matched non-dialysis patients were compared. Computed tomography scans of the dialysis patients (dialysis group with denosumab, n = 24; dialysis group without denosumab, n = 21) were obtained at baseline and at 6 months of follow-up.Results: At baseline, the dialysis group patients had a higher EATat-median (-71.00 H ± 10.38 vs. -81.60 H ± 6.03; p < 0.001) and CAC (1,223 A [248.50-3,315] vs. 7 A [0-182.5]; p < 0.001) than the non-dialysis group. At follow-up, the dialysis group without denosumab showed an increase in Agatston score (1,319.50 A [238.00-2,587.50] to 1,552.00 A [335.50-2,952.50]; p = 0.001) without changes in EATat-median (-71.33 H ± 11.72 to -70.86 H ± 12.67; p = 0.15). The dialysis group with denosumab showed no change in Agatston score (1,132.2 A [252.25-3,260.5] to 1,199.50 A [324.25-2,995]; p = 0.19) but a significant decrease of EATat-median (-70.71 H ± 9.30 to -74.33 H ± 10.28; p = 0.01).Conclusions: Denosumab may reverse EATat and retard CAC progression in dialysis patients with SHPT.","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"113-122"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000535882","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Denosumab preceding elective surgery is an alternative option when parathyroidectomy is not immediately possible. Denosumab (an osteoprotegerin mimic) may play a role in the cardiovascular system, which is reflected in the features of epicardial adipose tissue (EAT) and coronary artery calcification (CAC).

Methods: We investigated the effects of denosumab on EAT attenuation (EATat) and CAC in dialysis patients with secondary hyperparathyroidism (SHPT). This cohort study included patients on dialysis with SHPT. The baseline characteristics of dialysis patients and propensity score-matched non-dialysis patients were compared. Computed tomography scans of the dialysis patients (dialysis group with denosumab, n = 24; dialysis group without denosumab, n = 21) were obtained at baseline and at 6 months of follow-up.

Results: At baseline, the dialysis group patients had a higher EATat-median (-71.00 H ± 10.38 vs. -81.60 H ± 6.03; p < 0.001) and CAC (1,223 A [248.50-3,315] vs. 7 A [0-182.5]; p < 0.001) than the non-dialysis group. At follow-up, the dialysis group without denosumab showed an increase in Agatston score (1,319.50 A [238.00-2,587.50] to 1,552.00 A [335.50-2,952.50]; p = 0.001) without changes in EATat-median (-71.33 H ± 11.72 to -70.86 H ± 12.67; p = 0.15). The dialysis group with denosumab showed no change in Agatston score (1,132.2 A [252.25-3,260.5] to 1,199.50 A [324.25-2,995]; p = 0.19) but a significant decrease of EATat-median (-70.71 H ± 9.30 to -74.33 H ± 10.28; p = 0.01).

Conclusions: Denosumab may reverse EATat and retard CAC progression in dialysis patients with SHPT.

查看原文本刊更多论文

地诺单抗可减少继发性甲状旁腺功能亢进症和低骨量透析患者的心外膜脂肪组织衰减。

简介当甲状旁腺切除术无法立即进行时，在择期手术前使用地诺单抗是一种替代选择。地诺单抗（一种骨保护素模拟物）可能在心血管系统中发挥作用，这反映在心外膜脂肪组织（EAT）和冠状动脉钙化（CAC）的特征上：我们研究了地诺单抗对继发性甲状旁腺功能亢进症（SHPT）透析患者心外膜脂肪组织衰减（EATAT）和冠状动脉钙化（CAC）的影响。这项队列研究纳入了患有继发性甲状旁腺功能亢进症的透析患者。研究人员比较了透析患者和倾向评分匹配的非透析患者的基线特征。透析患者（使用地诺单抗的透析组，24 人；未使用地诺单抗的透析组，21 人）在基线和随访 6 个月时接受了计算机断层扫描：基线时，透析组患者的 EATAT 中位数（-71.00H±10.38 vs. -81.60H±6.03；P <0.001）和 CAC（1223A [248.50-3315] vs. 7A [0-182.5]；P <0.001）高于非透析组。随访时，未使用地诺单抗的透析组 Agatston 评分增加（从 1319.50A (238.00-2587.50) 到 1552.00A (335.50-2952.50)；P = 0.001），而 EATAT 中位数没有变化（从 -71.33H ± 11.72 到 -70.86H ± 12.67；P = 0.15）。使用地诺单抗的透析组的Agatston评分无变化（1132.2A（252.25-3260.5）至1199.50A（324.25-2995）；P = 0.19），但EATAT-中位数显著下降（-70.71H±9.30至-74.33H±10.28；P = 0.01）：结论：地诺舒单抗可逆转EATat，延缓SHPT透析患者的CAC进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiorenal Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-UROLOGY & NEPHROLOGY

CiteScore

5.40

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.